Medy-Tox   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2009
NCT01237977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Medy-Tox | Medytox Korea